Not a huge amount. The difference this time appears to be BIT has some clinical evidence that BIT225 lowers an immune activation market (sCD163). This is the data that is to be presented this week at the conference.
What this all means for the patients, how long the effect lasts, how quickly does HIV take to develop resistance to BIT225, and what the long term side effects of BIT225 will be are currently all unknown.
What’s new this time?, page-4
-
- There are more pages in this discussion • 80 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
